Si deseas distinguir tus productos, servicios o ambos de los de otra empresa, es posible que necesites una marca o nombre comercial. Descubre qué son, en qué consiste su procedimiento de registro y qué implica.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Si tienes un nuevo dispositivo, producto o procedimiento que resuelva un problema técnico o tenga una ventaja práctica, existen distintas formas de protegerlo en España y en otros países. Descubre cómo hacerlo.
¿Tu innovación reside en la estética, la ornamentación o la apariencia de tu producto? Protégela mediante un diseño industrial. Descubre qué derechos confiere el registro y cómo realizar la tramitación.
Las patentes publicadas en todo el mundo son una valiosa fuente de información científica, técnica y comercial.
El Bono 3 (Patentes Nacionales, Patentes Europeas, Informes Tecnológicos de Patentes y Búsquedas Retrospectivas) está cerrado desde el pasado 19 de junio. Se informará más adelante sobre su reapertura.
Si eres emprendedor/a o una empresa y quieres potenciar y mejorar la rentabilidad de tu negocio protegiendo de forma adecuada los activos intangibles de tu organización, en este espacio encontrarás lo necesario.
167
resultados
Última actualización
30/06/2025 [06:58:00]
Resumen de: AU2023401746A1
Techniques for performing application-layer security and communication over primary invitation channels arc disclosed. In certain embodiments, analyte data is obtained from an analyte sensor electrically coupled to a sensor electronics module of an analyte sensor system. A secret key is established with a display device over one or more primary invitation channels. The analyte data is encrypted using the secret key. The encrypted analyte data is broadcast over the one or more primary invitation channels.
Resumen de: US2025210156A1
Methods and system to provide glycemic control and therapy management based on monitored glucose data, and current and/or target HbA1C levels are provided.
Resumen de: US2025204814A1
A stretchable, conducting, and redox-active hydrogel with an interpenetrating double-network structure is provided. This structure is formed by infiltrating a brittle pure-gel conducting hydrogel with a stretchable hydrogel. Ferrocene derivatives are immobilized on the chains of the stretchable hydrogel through covalent bonds, and glucose oxidases are crosslinked to the stretchable hydrogel using a room-temperature crosslinker.
Resumen de: WO2025137110A1
Systems and methods are provided for sending a software update to an insulin pump and/or user device used with the insulin pump and selectively enabling and disabling certain functionality (e g., operations, tasks, functions, and/or features) enabled by the software update and/or settings adjusted by the software update. The software update may be in the form of a software package that is sent from a remote device to all insulin pumps or user devices on an insulin pump network. While all devices may receive the same software update it may be desirable to restrict certain functionality and/or settings for some insulin pumps and/or user devices. The insulin pump, user device associated with the insulin pump, and/or remote device in communication with the user device, may determine whether the functionality in the software update should be disabled or otherwise not enabled for a certain insulin pump and/or user device.
Resumen de: US2025204815A1
The present disclosure discloses a photoacoustic diagnostic device. More specifically, the present invention relates to a photoacoustic diagnostic device that detects ultrasound waves generated by irradiating a biological surface with a laser to noninvasively determine blood sugar concentration, or the like in a biological body. According to an embodiment of the present invention, the photoacoustic diagnostic device is equipped with a membrane element manufactured by a micro electro mechanical system (MEMS) process, and instead of mounting an expensive FFT, or the like on a transducer for receiving an ultrasound wave signal radiated from a subject and detecting a resonance peak or using a spectrum analyzer, by detecting multiple resonance peaks through multiple transducers with different resonance frequencies and combining the resonance peaks to perform analysis on blood sugar, or the like, it is possible to provide analysis results with high accuracy that are easy to implement and low cost.
Resumen de: US2025205427A1
Disclosed are techniques to establish initial settings for an automatic insulin delivery device. An adjusted total daily insulin (TDI) factor usable to calculate a TDI dosage may be determined. The adjusted TDI factor may be a TDI per unit of a physical characteristic of the user (e.g., weight) times a reduction factor. The adjusted TDI factor may be compared to a maximum algorithm delivery threshold. Based on the comparison result, the application or algorithm may set a TDI dosage and output a control signal. Blood glucose measurement values may be collected from a sensor over a period of time. A level of glycated hemoglobin of the blood may be determined based on the obtained blood glucose measurement values. In response to the level of glycated hemoglobin, the set TDI dosage may be modified. A subsequent control signal including the modified TDI dosage may be output to actuate delivery of insulin.
Resumen de: US2025204816A1
An apparatus for monitoring glucose according to an embodiment of the present invention includes an input unit that obtains first biometric information including a plurality of data points measuring glucose-related information of a subject; a noise removal unit that removes noise information included in the first biometric information; a preprocessing unit that preprocesses the first biometric information from which the noise information is removed to generate second biometric information having a lower sampling rate than the first biometric information; a compensation unit that generates compensation data based on the second biometric information and generates a calibration algorithm based on the compensation data; and a glucose level acquisition unit that acquires a glucose level related to the second biometric information by reflecting the calibration algorithm and a set time delay.
Resumen de: US2025204813A1
Devices, systems, and methods herein relate to managing a chronic condition such as diabetes. These systems and methods may obtain patient data from a plurality of devices, integrate the data for analysis of trends that may be presented to the patient and/or health care professional along with an actionable suggestion. In some variations, a method may include the steps of receiving analyte data generated by an analyte measurement device and patient data generated by a patient measurement device. One or more data trends may be generated by analyzing the analyte data against the patient data using a computing device. The device settings of one or more of the analyte measurement device and the computing device may be modified in response to one or more of the data trends.
Resumen de: WO2025134124A1
Embodiments of the disclosure generally relates to systems and methods for real time continuous monitoring of glucose. More specifically, the embodiments of the disclosure relate to a device for continuous glucose monitoring (COM), that includes subcutaneous electrochemical sensor, electronics, and algorithms to improve ease of manufacture, use, and more importantly, the welfare of people with diabetes.
Resumen de: EP4574039A1
An apparatus for monitoring glucose according to an embodiment of the present invention includes an input unit that obtains first biometric information including a plurality of data points measuring glucose-related information of a subject; a noise removal unit that removes noise information included in the first biometric information; a preprocessing unit that preprocesses the first biometric information from which the noise information is removed to generate second biometric information having a lower sampling rate than the first biometric information; a compensation unit that generates compensation data based on the second biometric information and generates a calibration algorithm based on the compensation data; and a glucose level acquisition unit that acquires a glucose level related to the second biometric information by reflecting the calibration algorithm and a set time delay.
Resumen de: EP4574038A2
Glucose and ketones may be dysregulated singularly or concurrently in certain physiological conditions and may be advantageously assayed together using an analyte sensor capable of detecting both analytes. Certain analyte sensors capable of dual detection may comprise a first working electrode and a second working electrode, a ketones-responsive active area disposed upon a surface of the first working electrode, a glucose-responsive active area comprising a glucose-responsive enzyme disposed upon a surface of the second working electrode, a membrane having a first portion overcoating the ketones-responsive active area and a second portion overcoating the glucose-responsive active area, in which the first portion and the second portion have different compositions. The ketones-responsive active area comprises an enzyme system comprising at least two enzymes that are capable of acting in concert to facilitate detection of ketones.
Resumen de: EP4576110A2
Embodiments described herein relate to a glucose monitoring system having a glucose sensor positioned in contact with interstitial fluid in a body of a user. A transmitter unit is coupled to the glucose sensor and processes data indicative of a plurality of monitored glucose levels from the glucose sensor. A receiver unit receives the processed data from the transmitter unit. The receiver unit comprises a processor and a user interface having a touch-sensitive display to render a plurality of display screens, including a home screen and an alert screen. The home screen is divided into a plurality of simultaneously displayed panels, with a first panel displaying the plurality of monitored glucose levels, a second panel simultaneously displaying a current glucose level and a glucose trend indicator, and a third panel displays status information of a plurality of components of the system. When an alarm condition is detected, the display renders the alert screen in place of one of the first panel, the second panel, or the third panel. The alert screen displays information corresponding to the detected alarm condition. The display affects a further output corresponding to the detected condition in response to user actuation of a portion of the display.
Resumen de: US2025176870A1
A device for determining a glucose concentration in an anterior chamber of a user's eye includes a VCSEL which emits laser light, and an optical element for influencing the laser light and/or an emergent light. The VCSEL and the optical element are configured such that the laser light enters the anterior chamber of the eye. The emergent light from the anterior chamber penetrates into the VCSEL. The device further includes an analysis unit that analyses a resulting self-mixing interference within the VCSEL to determine the glucose concentration.
Resumen de: EP4574023A1
A method for non-invasively estimating blood glucose for estimating a blood glucose value of a user by a computing device (400A, 400B, 2600). The method includes receiving a plurality of electrocardiogram (ECG) waveforms of the user, extracting at least two first ECG features from each of the plurality of ECG waveforms of the user, respectively determining a first feature peak position corresponding to each of the first ECG features, calculating at least one peak distance between the plurality of the first feature peak positions, and estimating the blood glucose value of the user based on the peak distance. The first ECG features are selected from the group consisting of a P-wave, a Q-wave, an R-wave, an S-wave, a T-wave, and a U-wave. Furthermore, a computing device (2600) for non-invasively estimating blood glucose, a device (2700) for non-invasively measuring ECG signal, and a non-transitory computer readable storage medium are utilized for the method.
Resumen de: WO2025127627A1
The present invention relates to an exercise management method and system for managing blood sugar variability. The method according to the present invention comprises the steps of: obtaining data on the timing of postprandial blood sugar spikes on the basis of a user's blood sugar data acquired during a first period; calculating an optimal start time for postprandial aerobic exercise on the basis of the data on the timing of postprandial blood sugar spikes; and providing an alert for the start time of postprandial aerobic exercise on the basis of the optimal start time for postprandial aerobic exercise during a second period. According to the present invention, it is possible to recommend an effective postprandial aerobic exercise time tailored to a user's blood sugar pattern. In addition, it is possible to prompt a user to start aerobic exercise at the optimal time point for postprandial aerobic exercise according to the meal. Furthermore, by analyzing and providing the improvement in blood sugar levels of postprandial aerobic exercise, the user's will to perform postprandial aerobic exercise can be encouraged and adherence to exercise can be enhanced.
Resumen de: WO2025128082A1
A system and method for wireless transmission of glucose data. According to an embodiment of the present disclosure, there is provided a system, including: a glucose sensor; a beacon transmitter; and a processing circuit connected to the glucose sensor and the beacon transmitter, the processing circuit being configured to transmit a data packet, the data packet including measurement data including a measurement value, the measurement value being based on a glucose measurement.
Resumen de: US2025195196A1
The development of devices for a functional cure for diabetes by mimicking native pancreatic tissue for production of all pancreatic hormones. A physiologically and mechanically biocompatible artificial pancreas, wherein the pancreas comprises a combination of a PVA hydrogel combined with cells selected from the group consisting of islets; clusters of islets; Beta cells, and combinations of islets and Beta cells. The bioartificial pancreas contains vascular grafts therein or thereon a wall of the pancreas so that said grafts are an integral part of the wall of the bioartificial pancreas. The grafts can be anasmotized to living blood vessels in the body.
Resumen de: US2025195000A1
A wearable smart insole for a user having foot having a planter arch and a medial plantar artery (MPA) along the plantar arch is provided. The insole has at least one optical sensor disposed in the insole along the MPA, a power handling circuit, an energy storage module operatively coupled with the power handing circuit to provide power to the optical sensor. The optical sensor is disposed along the MPA in the insole and provides a signal for obtaining heart rate data, blood oxygen saturation data and blood glucose measurements. Two optical sensors may be provided along the MPA to provide signals for calculating blood pressure. A third optical sensor may be provided along the lateral plantar artery to provide signals to detect diabetes or arterial disease.
Resumen de: US2025194964A1
The present invention relates generally to systems, devices, and methods for in vivo monitoring of an analyte level. In particular, the present invention relates to sensors having saccharides or similar molecules present in glucose-oxidase containing sensing layers to improve sensor stability.
Resumen de: US2025197515A1
The present invention provides pharmaceutical formulations comprising a human antibody that specifically binds to human interleukin-6 receptor (hIL-6R). The formulations may contain, in addition to an anti-hIL-6R antibody, at least one amino acid, at least one sugar, and/or at least one non-ionic surfactant. The pharmaceutical formulations of the present invention exhibit a substantial degree of antibody stability after storage for several months.
Resumen de: US2025195781A1
Disclosed are systems and methods for a computerized framework that electronically manages and controls a patient's therapy for proper administration of diabetic treatment. The framework includes a disposable pen injector that has integrated therein dose logging capabilities (e.g., a NFC circuit) for controlling the administration of the prescribed therapy. Electronic communications between the disposable pen injector and a therapy control application executing on a patient's device can effectuate accurate and efficient administration of prescribed therapy. The pen can communicate information to the patient's device, and the application executing thereon, that includes dosage information related to availability left in the pen, timing of doses, and the like. In a related manner, the application can compile dosage planning information that can dictate types of doses, amounts of doses, timing of doses, and the like, to ensure that the patient is complying with a prescribed diabetic prescription.
Resumen de: US2025195761A1
Systems and methods are provided for sending a software update to an insulin pump and/or user device used with the insulin pump and selectively enabling and disabling certain functionality (e.g., operations, tasks, functions, and/or features) enabled by the software update and/or settings adjusted by the software update. The software update may be in the form of a software package that is sent from a remote device to all insulin pumps or user devices on an insulin pump network. While all devices may receive the same software update it may be desirable to restrict certain functionality and/or settings for some insulin pumps and/or user devices. The insulin pump, user device associated with the insulin pump, and/or remote device in communication with the user device, may determine whether the functionality in the software update should be disabled or otherwise not enabled for a certain insulin pump and/or user device.
Resumen de: EP4552558A2
The present disclosure relates to a body attachment unit for continuous blood glucose measurement, in which the body attachment unit is manufactured so as to be assembled in an applicator, thereby minimizing additional work and allowing attachment of the body attachment unit to a body simply by operation of the applicator. In particular, a wireless communication chip is provided in the body attachment unit to enable communication with an external terminal, thereby enabling simple and convenient use without performing additional work of connecting a separate transmitter, and allowing easier maintenance. In addition, activation occurs by a user's operation after the body attachment unit is attached to the body, such that an activation start point in time can be adjusted to an appropriate point in time according to the user's needs, and activation occurs in a stabilized state, thereby providing the body attachment unit allowing more accurate blood glucose measurement.
Resumen de: US2025195753A1
A method of infusing liquid medicaments including insulin via an insulin pump, includes identifying an insulin delivery protocol associated with ingestion of carbohydrates wherein the insulin delivery protocol is likely to lead to a postprandial drop in blood glucose to a level below a basal level, then proposing at least one alternative insulin delivery protocol to inhibit the postprandial drop in blood glucose by delivering a metered amount of insulin that is appropriate to facilitate the metabolism of the carbohydrates without the postprandial blood glucose level drop. The invention further includes querying the patient as to whether to apply the alternative insulin delivery protocol, receiving instructions from the patient in response to the query, and applying the alternative insulin delivery protocol following receiving instructions from the patient to apply the alternative insulin delivery protocol.
Nº publicación: US2025195755A1 19/06/2025
Solicitante:
AITA BIO INC [US]
AITA BIO INC
Resumen de: US2025195755A1
A device for delivering medicament to a user is disclosed. The device is configured to be mounted to the user. The device comprises a baseplate including: an inlet opening and outlet opening to align with an inlet opening and outlet opening of a micropump, respectively; a first port for fluid in fluid communication with a catheter; and a first fluid channel to enable fluid communication between the first port and the outlet opening of the micropump; and a housing configured to engage the baseplate to form an interior therein, the interior including a first internal region that is sealed from fluid ingress and a second internal region that is not sealed from fluid ingress, wherein the inlet opening of the baseplate, the outlet opening of the baseplate and the first port are within the first internal region.
BOPI
Sede Electrónica
